Name of Study: DCE-MRI PET Bevacizumab Study in Rectal Cancer: A phase II/pharmacodynamic study of preoperative or definitive FOLFOX plus bevacizumab, with the additional pharmacodynamic goal of assessing tumor blood flow as measured by dynamic contrast enhanced MRI, and the induction of hypoxia and apoptosis as measured by PET in patients with rectal cancer
Rectal cancer is treated with chemoradiation (combination of chemotherapy and radiation) prior to surgery, if possible. The purpose of this is to attack cells that might have already escaped the tumor, and to shrink the tumor to make surgery possible or more successful.
We know that adding bevacizumab (Avastin) after surgery doesn’t add much benefit. But there is increasing evidence that adding bevacizumab early – before surgery - may be a useful strategy. This trial will examine the effects of bevacizumab with chemotherapy and radiotherapy to improve long term results from this treatment.
Patients already deemed candidates for surgery:
Patients with advanced disease who are not considered candidates for surgery: